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Sleeping sickness or human African trypanosomiasis in
West and Central Africa is caused by Trypanosoma brucei
gambiense. The infection progresses from a haemo-lym-
phatic or first stage to a meningo-encephalitic or second
stage, once parasites reach the central nervous system.
After treatment, trypanosomiasis patients should be fol-
lowed for 2 years before they can be considered cured.
Relapse after treatment is unambiguously diagnosed by
the presence of trypanosomes in blood, lymph and/or cer-
ebrospinal fluid. If trypanosomes are not detected, diag-
nosis of relapse is based on the absolute number of, and/
or increase in white blood cells in cerebrospinal fluid with
or without neurological symptoms. Currently, white
blood cell count based criteria to define relapse or cure are
not standardized. As a consequence, the impact of the dif-
ferent criteria for relapse on the outcome and comparabil-
ity of clinical trials remains unknown.
The specificity, sensitivity and time to diagnosis of 10 cri-
teria for relapse based on trypanosome detection and/or
the white blood cell count in cerebrospinal fluid were
compared in 63 relapsed and 247 cured Trypanosoma bru-
cei gambiense patients. Among the criteria in use, the "pres-
ence of trypanosomes or a cerebrospinal white blood cell
count ≥ 50/μl" can be recommended as the criterion to
identify relapses after treatment for Trypanosoma brucei
gambiense human African trypanosomiasis, irrespective of
disease stage.
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